Fig. 2From: The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritisDensity plots of changes from baseline to weeks 4, 12 for C1M, C3M, and C4MBack to article page